Clinical Trials
4 trialsNCT04300556 2026-06-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT03829332 2026-02-19
LEAP-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976375 2025-08-15
LEAP-008
Merck Sharp & Dohme LLC
Phase 3 Completed